Trade Neurocrine Biosciences, Inc. - NBIX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.84 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 143.2 |
| Open | 143.38 |
| 1-Year Change | 4.52% |
| Day's Range | 143.38 - 146 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | 145.36 | 1.46 | 1.01% | 143.90 | 146.17 | 142.96 |
| Jan 17, 2025 | 142.95 | 1.89 | 1.34% | 141.06 | 144.74 | 141.04 |
| Jan 16, 2025 | 141.72 | 0.51 | 0.36% | 141.21 | 143.30 | 140.01 |
| Jan 15, 2025 | 142.00 | 2.10 | 1.50% | 139.90 | 142.53 | 137.93 |
| Jan 14, 2025 | 139.36 | -1.59 | -1.13% | 140.95 | 144.09 | 138.91 |
| Jan 13, 2025 | 142.92 | 3.38 | 2.42% | 139.54 | 143.15 | 137.29 |
| Jan 10, 2025 | 140.81 | 3.57 | 2.60% | 137.24 | 142.75 | 136.59 |
| Jan 8, 2025 | 138.49 | 1.59 | 1.16% | 136.90 | 139.05 | 135.77 |
| Jan 7, 2025 | 137.04 | 0.83 | 0.61% | 136.21 | 138.95 | 136.12 |
| Jan 6, 2025 | 136.35 | -1.66 | -1.20% | 138.01 | 139.36 | 136.00 |
| Jan 3, 2025 | 137.73 | 0.68 | 0.50% | 137.05 | 139.00 | 136.97 |
| Jan 2, 2025 | 137.25 | 0.85 | 0.62% | 136.40 | 139.29 | 136.15 |
| Dec 31, 2024 | 136.41 | -0.44 | -0.32% | 136.85 | 138.40 | 135.76 |
| Dec 30, 2024 | 136.60 | -0.02 | -0.01% | 136.62 | 138.60 | 135.93 |
| Dec 27, 2024 | 138.87 | 0.47 | 0.34% | 138.40 | 139.63 | 137.95 |
| Dec 26, 2024 | 138.54 | 3.30 | 2.44% | 135.24 | 138.99 | 134.95 |
| Dec 24, 2024 | 136.06 | -1.39 | -1.01% | 137.45 | 137.53 | 134.73 |
| Dec 23, 2024 | 136.35 | 1.41 | 1.04% | 134.94 | 136.97 | 132.50 |
| Dec 20, 2024 | 134.84 | 2.26 | 1.70% | 132.58 | 136.82 | 132.58 |
| Dec 19, 2024 | 134.78 | -0.04 | -0.03% | 134.82 | 136.25 | 132.55 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Neurocrine Company profile
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Neurocrine Biosciences, Inc. revenues increased 8% to $1.13B. Net income decreased 78% to $89.6M. Revenues reflect Net product sales increase of 10% to $1.09B. Net income was offset by General and administrative -others increase of 36% to $497.5M (expense), Research and development - others increase of 16% to $279.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 110M auth. 55,200,641 issd. Insiders own 1.73%. IPO: 5/96, 4,394,286 shares (1,214,286 by the Company) @ $10.50 by Robertson, Stephens & Co. LLC. PO: 12/00, 3M shares @ $30 by Robertson Stephens. PO 12/01, 3.5M shares @ $46.75 by Deutsche Banc Alex. Brown. FY'00 Q's are restated.
| Industry: | Bio Therapeutic Drugs |
12780 El Camino Real
SAN DIEGO
CALIFORNIA 92130-2042
US
News
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
15:24, 21 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024People also watch
Still looking for a broker you can trust?
Join the 680,000+ traders worldwide that chose to trade with Capital.com